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Abstract 
Purpose: To investigate the influence of dexmedetomidine on the effect of ketamine on developing 
spinal cord.  
Methods: Postnatal day 3 (P3) and postnatal day 7 (P7) rat pups received intrathecal ketamine (10 
mg/kg b.wt) and/or dexmedetomidine (10 µg/kg b.wt). Spinal reflex function was assessed by evaluating 
the sensory stimuli based on mechanical withdrawal threshold. Spinal tissue was analysed for activated 
caspase-3 using monoclonal anti-activated caspase-3. Apoptosis count of the spinal tissue was also 
measured by Fluoro-Jade C staining while glial reactivity was assessed by ionized calcium binding 
adapter molecule 1 on Day 7 day following injection. Long-term spinal function in rat pups on postnatal 
day 35 (P35) was evaluated by measuring the hindlimb withdrawal threshold and gait analysis.  
Results: Exposure to intrathecal ketamine at 10 mg/kg in P3 and P7 pups decreased mechanical 
withdrawal thresholds and increase apoptosis and microglial activation in the spinal cord. Altered spinal 
function, as presented by a decrease in mechanical withdrawal threshold and altered static gait, was 
observed in P35 rats exposed to intrathecal ketamine on P3. Dexmedetomidine administration did not 
alter the spinal function and histology of spinal tissue. Co-administration of dexmedetomidine and 
ketamine suggests that the former reduced apoptosis counts, altered glial responses, increased 
mechanical withdrawal threshold and improved gait.  
Conclusion: Dexmedetomidine protects against intrathecal ketamine-induced spinal toxicity in neonatal 
rats.  
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The effective use of spinal anaesthesia in 
neonates and infants has been well established 
in paediatric practice [1,2]. Series of studies have 
reported safe and effective use of anaesthesia 
and analgesia in paediatric practice [3]. In pre-
term neonates susceptible to post-operative 
apnoea or having co-existing respiratory disease 
neuraxial anaesthesia is largely used [4]. There 
is mounting evidence that the systemic general 
anaesthetics with n-methyl-D-aspartate (NMDA) 
antagonist or γ-amino butyric acid agonist action 
can cause apoptosis of the developing brain cells 
in rodents [5]. The use of neuraxial anaesthesia 
and analgesia could avoid or minimize the 
exposure to general anaesthetics in neonates 
and infants. 
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Non-competitive NMDA receptor antagonist, 
ketamine is widely used in paediatric 
anaesthesia to provide sedation and analgesia 
[6]. However, the developing brain is highly 
susceptible to anaesthesia. Repeated exposure 
to ketamine and other NMDA antagonists have 
been reported to cause neuroapoptosis in the 
developing brain of neonatal rats [7]. Other than 
systemic administration/route, ketamine is also 
administered spinally in combination with local 
anaesthetic to extend the duration and to 
improve the analgesic effect [8]. Spinal cord 
toxicity has been reported in ketamine-induced 
adult animals [9]. Intrathecal ketamine has been 
reported to induce spinal toxicity in neonatal rats 
[10]. 
 
Dexmedetomidine, a potent α2- adrenoceptor 
agonist, has a broad safety margin and has 
excellent analgesic, sedative, and anaesthetic-
sparing properties. It has also been reported to 
have neuroprotective effects in animal models 
[11]. Studies have demonstrated that 
dexmedetomidine reduced the required dose of 
ketamine and is also effective in attenuating the 
cardio-stimulatory and adverse effects of 
ketamine in non-human primates [12]. It remains 
unknown as to whether dexmedetomidine could 
possibly also attenuate ketamine-induced spinal 
toxicity. The aim of this study was to evaluate 
whether dexmedetomidine administration after 
intrathecal injection of ketamine can prevent 




All experiments were carried out according to 
protocols approved by the Institutional Animal 
Care and Use Committee of the Affiliated 
Hospital of Qingdao University, Shandong, 
China. Pregnant Holtzman Sprague-Dawley rats 
(Harlan, Indianapolis, IN) were housed in 
accordance with the guidelines for laboratory 
animals [13] in a 12 h light-dark cycle and 
provided with free access to standard feed and 
water. The litter day of the pups was noted. The 
pups were randomly assigned to treatment 
groups containing equal numbers (n = 10/group) 
of males and females at postnatal day 3 (P3) or 
day 7 (P7). Body weights of the rat pups were 
between 8 - 11 g at P3 and 12 - 18 g at P7. The 
animals were regularly monitored and maintained 
until further testing at 5 weeks of age. For all 
experimental interventions, rat pups were kept on 
heating pad (36 °C - 37 °C) in order to maintain 
body temperature. Proper care was taken to 
minimize the duration of maternal separation and 
handling of the pups as well.  
 
All chemicals used in the study were purchased 
from Sigma Aldrich, MO, USA, unless otherwise 
specified.  
 
Intrathecal injection  
 
Pups were anesthetized with isoflurane (3 - 5 %) 
in oxygen and air. Percutaneous intrathecal 
injections were made at the low lumbar level 
(intervertebral space L4-5 or L5-L6) with a 30-
gauge needle perpendicular to the skin. Injection 
volumes of 0.5 µl/g bodyweight (previously 
determined) [14], were delivered using a hand-
driven micro-injector (P3 and P7). Doses 
administered were 10 mg/kg body weight of 
ketamine (ketamine hydrochloride), and 10 µg/kg 
body weight of dexmedetomidine 
(dexmedetomidine hydrochloride). The control 
P3 (P3C) and P7 (P7C) pups received no 
anaesthesia. The treatment pups received 
ketamine (P3K), ketamine and dexmedetomidine 
(P3KD), and dexmedetomidine (P3D) 
respectively. Similar administration was given to 
P7 pups P7K, P7KD and P7D. 
 
Behavioural testing and assessment of spinal 
reflex function 
 
Mechanical withdrawal threshold  
 
The P3 and P7 rat pups were tested for 
mechanical withdrawal threshold. The threshold 
was determined using calibrated von Frey 
filaments. The von Frey filaments apply 
logarithmically increasing pressure (0.4 to 15 g). 
Pups were lightly restrained on a flat surface and 
well calibrated von Frey hairs device (electronic 
von Frey device, Stoelting, IL, USA) that deliver 
increasing mechanical stimuli which were applied 
to the dorsal surface of the hind paw of the pups 
five times with one second intervals [15]. The 
number of evoked withdrawal responses to each 
stimulus of increasing intensity was recorded 
until a given stimulus evoked five responses or a 
supra-threshold cut-off pressure was reached 
[15]. Mechanical withdrawal thresholds were 
measured in both hind limbs at 15, 30 and 45 
min following intrathecal injections. 
 
Separate groups of P3 rat pups (n = 10) received 
intrathecal injections as described above. The 
pups were maintained under standard conditions 
as previously described until P35. Spinal cord 
function was assessed at P35 by evaluating hind 
limb withdrawal reflex responses to mechanical 
stimuli [16]. The mechanical stimulus using 
electronic von Frey device was applied to the 
mid-plantar surface of the hind paw as previously 
described under acute withdrawal test.  
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Gait analysis at P35 
 
P35 pups that received intrathecal injections at 
P3 were assessed for gait. These experiments 
were performed as described earlier [10,14]. Gait 
analysis was performed as the animal crossed 
the glass runway of the CatWalK® system 
(version 7.1.6) (Noldus Information Technology, 
Wageningen, The Netherlands). At P22 - 25, the 
rats were placed on one end of the runway and 
allowed to explore the environment for about 5 
min for three consecutive days.  
 
The rats were trained, as previously described 
[17,18] with runway crossings toward feed 
rewards at the farther end. At P35, runway 
crossings of the rats were recorded. The values 
were included for analysis, provided the maximal 
time for crossing the 60-cm-long section of the 
runway used for gait recording was ≤ 2 sec, and 
when there were no intermediate stops during 
the crossing. Three crossings per animal were 
analyzed using the CatWalk® 7.1.6 software.  
 
Spinal cord tissue preparation and staining 
 
Tissue analysis was performed 24 h or 7 days 
following intrathecal injections. The rat pups that 
were terminally anesthetized with pentobarbital 
(100 mg/kg, i.p) were transcardially perfused with 
saline followed by 4 % paraformaldehyde. The 
spinal cord were dissected and fixed in 4 % 
paraformaldehyde overnight, transferred to 30 % 
sucrose solution and stored at 4 °C. The 
transverse sections of lumbosacral spinal cord (7 
and 14 μm) were excised using a cryostat and 
fixed on slides and stored at -30 °C. 
 
Activated caspase-3 assay  
 
To assess apoptosis, spinal tissue obtained from 
P3 and P7 animals 24 h following intrathecal 
injection was stained for activated caspase-3. 
The slides were incubated in 3 % peroxidase for 
10 min, blocked with 0.3 % Triton X-100 and 5 % 
normal goat serum in Tris-buffered saline for one 
hour at room temperature, followed by incubation 
with rabbit monoclonal anti-activated caspase 3 
(1:100; Cell Signalling, Danvers, MA,USA) 
overnight at 4 °C. Biotinylated goat anti-rabbit 
secondary antibody (Vector Laboratories, 
Burlingame, CA, USA) was applied at 1:250 for 
30 min at room temperature. The slides were 
further incubated with avidin-biotin-peroxidase 
complex (Vector Laboratories, Burlingame, CA) 
for 30 min and developed with 3,3’-
diaminobenzidine (DAB) for 8 min. The slides 
were counterstained with hematoxylin, 
dehydrated and observed.  
 
Fluoro-Jade C staining 
 
Fluoro-Jade C staining was performed in 14 μm 
sections of spinal cord obtained 24 h after 
injection. The staining was done using Fluoro-
Jade C staining kit (Biosensis, USA) following the 
manufacturer’s instructions. Fluoro-Jade C 
immunfluorescent positive cells were counted 
under the fluorescent microscopy. 
 
Evaluation of ionized calcium binding adapter 
molecule 1 (Iba1) 
 
Spinal cord sections (14 μm thick) were 
evaluated 7 days following injection for glial 
reactivity with microglial (Iba1) marker. The 
slides after washing with Triton X-100 (0.1 % in 
phosphate buffered saline), were incubated in 5 
% goat blocking serum at room temperature for 
60 min, followed by incubation with rabbit anti-
Iba1 (1:1000; WAKO Chem, Irvine, CA, USA) for 
48 h at 4 °C. The slides were further incubated 
with fluorescent secondary antibodies for 2 h 
(1:250 goat anti-mouse Alexa 555 and 1:250 
goat anti-rabbit Alexa 488; Abcam, USA). Slides 
were cover-slipped with prolong gold antifade 
mounting media with 4’,6-diamidino-2-
phenylindole (DAPI). The sections were imaged 
using an Olympus BX51 (Olympus America, Inc., 
Center Valley, PA, USA) equipped with a digital 
camera and image-capture software. The mean 
intensity of immunofluorescence was calculated 
using Image Pro Plus software (Media 




The data are presented as mean ± SD and were 
analysed using SPSS version 17.0 software. One 
way ANOVA (p < 0.05) followed by DMRT 




Mechanical withdrawal threshold 
 
The mechanical withdrawal thresholds following 
intrathecal ketamine were observed to be 
markedly lower in P3 and P7 at 15 and 30 min 
when compared to control pups (Figure 1). 
 
The threshold values were lower at 45 min 
however the values did not show a significant 
change as compared to control pups. The 
threshold levels of P3KD and P7KD were 
observed to be slightly higher than the ketamine 
treated P3K and P7K pups (Fig 2). Intrathecal 
dexmedetomidine at P3 and P7 presented  
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Figure 1: Mechanical withdrawal thresholds (determined by von Frey Filaments) of P3 (A) and P7 (B) rat pups at 
15, 30 and 45 min following intrathecal injections. Values are represented as mean ± SD (n = 6);     Symbol key: 
◊ = control; o = ketamine;▲ = ketamine+dexmedetomidine; ∎ = dexmedetomidine 
 
 
Figure 2: Mechanical withdrawal thresholds 
(determined by von Frey Filaments) of at P35 pups 
that received intrathecal injections on P3. Values are 
represented as mean ± SD 
 
mechanical threshold levels almost similar to 
P3C and P7C, except for at 15 min where the 
values were less compared to P3C and P7C. 
Separate groups of rat pups receiving ketamine 
at P3 were evaluated at P35. At P35, mechanical 
withdrawal thresholds were lower in the P3 
ketamine group compared with the P3C group (p 
< 0.05). However, groups that received 
dexmedetomidine alone and ketamine + 
dexmedetomidine showed threshold values that 
differed non-significantly against control pups 
that received neither dexmedetomidine nor 
ketamine. 
 
Gait analysis  
 
Gait analysis was performed using the CatWalk® 
runway system at P35. The system records both 
static and dynamic parameters such as paw 
pressure, print area, duty cycle, stride length as 
well as interlimb coordination. Ketamine 
injections at P3 resulted in a marked (p < 0.05) 
decrease in paw print area and paw print 
intensity. However the decreases in dynamic 
parameters were not significant (Table 1). The 
treatment with intrathecal injections of ketamine 
+ dexmedetomidine and dexmedetomidine did 
not result in considerable alterations in gait as 
compared to the control pups. 
 
 
Table 1: Gait parameters for rat pups exposed to anaesthesia 
  
Group 











P3C 43.10± 1.06 b 170.20 ± 10.10c 99.9 ±  0.16a 59.25 ± 1.14a 109.70 ± 9.36a 32.9 ± 1.21 a 
P3K 20.25± 0.68 a 120.25 ± 9.15a 95 ± 0.69a 54.35 ± 1.38a 100.10 ± 8.65a 27.10 ± 1.01 a 
P3KD 38.50±  2.01b 158.80 ± 11.21b 98±  0.53a 56.20 ± 2.05a 109.16±  9.81a 33.15 ± 1.00 a 
P3D 39.10± 0.56b 160.10 ±  7.36b 99 ± 0.25a 58.75 ± 2.10a 108.25 ± 3.45a 33.80 ± 0.96 a 
Values are represented as mean ± SD (n = 10); values within the same column that share a common alphabet do 
not differ significantly (ANOVA, p < 0.05) followed by DMRT analysis; Paw Print area = surface area of floor 
contacted by hindpaw; Paw Print intensity = intensity of pixels forming area of paw contact; Regularity index = 
index for degree of interlimb coordination during gait; Stability of gait = distance between two hindpaws measured 
perpendicular to walking direction; Stride length = distance between placement of hindpaw and subsequent 
placement of same paw; Duty cycle = ratio between stance duration and full stepcycle duration 
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Activated caspase-3 was detected in the spinal 
tissue sections to identify apoptotic neurons. The 
number of apoptotic cell profiles was significantly 
(p < 0.05) increased (Figure 3) 24 h subsequent 
to intrathecal ketamine of 10 mg/kg, in P3K and 
in P7K pups (p < 0.05).  
 
In P3KD and P7KD animals, apoptotic cell count 
increases following intrathecal injections of 
ketamine and dexmedetomidine were not 
statistically significant when compared with 
respective control pups. The increase was 
slightly lesser in P7 pups when compared to P3 
pups. The rise in apoptotic cells in intrathecal 
dexmedetomidine administration in P3 and P7 




The number of Fluoro-Jade C positive cells in 
spinal cord sections of the rat pups at P3 and P7 
following 24 h after injections are represented in 
Figure 4. The results reveal a significant (p < 
0.05) increase in the Fluoro-Jade C positive cell 
counts 24 h after injections of 10 mg/kg ketamine 
in the P3K pups as compared to control P3 pups. 
The number was slightly reduced in the P3KD 
pups and significantly less in the P3D pups as 
against P3K pups treated with ketamine alone. 
Following ketamine at P7 there was a slight 
increase in positive cell counts in P7K as against 
P7C that was not statistically significant. Fluoro-
Jade C positive cells were rarely observed in the 
P7KD and in P7D pups, however the counts 








Figure 3: Activated caspase-3 immunostaining following intrathecal injections in P3 and P7 rats pups; (A) 
Representative sections of spinal cord (a) Control; (b) 24 h after injections; (B) Activated caspase-3 
immunopositive cell counts 24 h after intrathecal injections; values represented as mean ± SD ( n=3). * 
represents values that vary significantly at p < 0.05 
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Ionized calcium binding adapter molecule 1 
(Iba1) 
 
Glial reactivity was assessed by detecting 
ionized calcium binding adapter molecule 1 
(Iba1). Iba1 immunoreactivity in the spinal cord 
increased 7 days following injection of intrathecal 
ketamine 10 mg/kg in P3 pups (Figure 5). No 
significant change was observed following 
ketamine injection in P7 pups as well in P3KD 
and P7KD pups. Intrathecal dexmedetomidine 
administration also resulted in no significant 





Ketamine, a non-competitive NMDA receptor 
antagonist is a widely used dissociative 
anaesthetic agent, and blockade of NMDA 
receptors is known to cause neurotoxicity [7,19]. 
In the present study, the influence of 
dexmedetomidine administration on the effect of 
intrathecal ketamine in neonatal rat pups was 
evaluated. The spinal function was assessed by 
mechanical withdrawal threshold and gait 
parameters at P35. The hind paw withdrawal 
threshold was determined using von Frey hairs 
and was expressed in grams. The animal’s 
response to these filaments was used to 
determine mechanical withdrawal thresholds. 
Usually, a paw withdrawal upon probing or 
immediately upon release of the filament is 
considered a positive response [20]. The results 
of the study revealed the spinal toxicity of 
intrathecal ketamine administration at P3 and P7, 
as evidenced by a lower threshold levels that 
improved on administration of dexmedetomidine. 
 
Figure 4: Apoptopic cell counts by Fluoro-Jade C staining. Apoptotic cell counts in spinal cord sections of P3 rat 
pups after intrathecal injections; values presented as mean ± SD (n = 3); * represents values that vary 




Figure 5: Ionized calcium binding adapter molecule 1 (Iba1) immunoreactivity. Immunofluorescence presented 
as % change in positive area fraction compared with control animals; values are presented as mean ± SD (n = 3); 
* represents values that vary significantly (p < 0.05) 
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Following intrathecal ketamine at P3, mechanical 
withdrawal threshold was reduced at P35. 
Likewise, NMDA antagonist MK-801 placed over 
the spinal cord of P0-1 pups as a slow release 
formula [21] revealed persistent changes in 
mechanical sensitivity, and the level of change 
was greater with extended blockade. 
 
Local anaesthetics may have other toxic effects 
that are not related to developmental apoptosis 
and that which influence both motor and sensory 
outcomes. Recent studies have demonstrated 
that local anaesthetic causes changes in thermal 
tail flick latency, mechanical paw pressure 
withdrawal threshold and motor function 4 to 7 
days following doses of local anaesthetic [21]. 
The gait analysis of experimental animals was 
performed by the CatWalk system, which is a 
video-based automated gait analysis system that 
evaluates gait changes in rodents [22]. 
Intrathecal ketamine injection resulted in 
alterations in the gait parameters. Hind paw print 
area and print intensity decreased following 
intrathecal ketamine injections at P3, suggesting 
impairments in placement of the paw on the 
glass during the static phase of walking. Walker 
et al [10] also reported a similar finding. Marked 
decreases in hind paw print area and print 
intensity evocative of allodynia have been 
observed to be associated with pain as in 
monoarthritis [23], and in conditions of peripheral 
nerve lesions [18]. Subsequent to P3 ketamine 
administration, duty cycle was decreased, 
because the time hind paw was in contact with 
the surface during gait was decreased. However, 
the differences were not statistically significant. 
The results of dynamic parameters - stride 
length, gait regularity and stability suggested that 
gait coordination was slightly decreased as 
against control pups. In animals that received 
intrathecal ketamine and dexmedetomidine, 
there was a marked improvement in gait. The 
static parameters were increased markedly as 
against pups that received intrathecal ketamine 
alone. Similar results were observed in 
dexmedetomidine alone administered rat pups. 
The print area and print intensity of the pups 
were almost near control values. Intrathecal 
dexmedetomidine could possibly offer protection 
against ketamine-induced alterations in gait.  
 
The developing spinal cord be susceptible to 
apoptosis, which increases following prolonged 
general anaesthesia at P7 [24] and as well to 
analgesic doses of intrathecal ketamine at P3 
[10]. Although apoptosis has been reported in 
spinal cord following anaesthesia at P7 [21], the 
period of peak susceptibility to spinal toxicity 
differs. It has been reported that the degree of 
developmental apoptosis in the lumbar spinal 
cord changes with age [25]. In the present study, 
the results obtained indicate that the level of 
apoptosis was markedly greater than for P7 
pups. Activated caspase-3, an enzyme in the 
apoptotic cascade, identifies neurons that have 
progressed beyond the point of commitment to 
cell death [26]. Antibodies to activated caspase-3 
have been employed to assess neuronal 
apoptosis and Fluoro-Jade C, a sensitive marker 
of neuronal degeneration [10] was used to 
determine cellular degeneration. In the spinal 
cord, the number of apoptotic profiles was 
increased by 2 folds following intrathecal 
ketamine in line with previous reports [10]. 
Administration of dexmedetomidine alone and 
with ketamine resulted in lesser apoptotic cell 
counts as measured by caspase-3 and Fluoro-
Jade C staining.  
 
Neuronal apoptosis was increased by intrathecal 
ketamine along with increased microglial 
activation 7 days following ketamine injection and 
changes in sensory threshold and gait, several 
weeks later. Ionized calcium binding adaptor 
molecule 1 (Iba1) is a microglia/macrophage-
specific calcium-binding protein. Iba1 participates 
in membrane ruffling and phagocytosis in 
activated microglia. Previous studies have shown 
activation of microglia commonly occurring in the 
early response of the CNS to a wide variety of 
pathological stimuli, including axotomy, trauma, 
inflammation, degeneration, and ischemia [27]. 
Several studies also have suggested that 
microglia may be rapidly and time-dependently 
activated after ischemia, and the activation may 
reflect the extent of severity of ischemic injury 
[28]. Iba1 thus serves as a marker in pathological 
conditions. Microglia has been known to exert 
dual effects on the CNS [27]. It is involved in 
neuro-protection by secretion of several 
neurotrophins and elimination of microorganisms 
and deleterious debris [29]. In contrast, microglia 
also exerts neurotoxic effects by releasing 
reactive oxygen species, nitric oxide, or 
inflammatory cytokines, which may cause 
neuronal damage [30]. 
 
In the present study, the marked increase in Iba1 
in the ketamine treated pups is suggestive of the 
microglial activation. This could be either due to 
its neuro-protective or neurotoxic effects under 
the influence of ketamine. Nevertheless, the 
considerable decrease in the level of Iba1 in the 
pups treated with dexmedetomidine either alone 
or along with ketamine is suggestive of the 
protective effect of dexmedetomidine. Studies 
have shown the neuro-protective properties of 
dexmedetomidine [31]. These data suggested 
that dexmedetomidine might be helpful in 
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The observed results of mechanical withdrawal 
and gait analysis are in line with neuronal 
apoptotic cell counts. Thus, dexmedetomidine 
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